Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment

Immunocompromised patients are at increased risk for a severe course of COVID-19. Treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with anti-SARS-CoV-2 monoclonal antibodies (mAbs) has become widely accepted. However, the effects of mAb treatment on the long-term p...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Laura Thümmler, Margarethe Konik, Monika Lindemann, Neslinur Fisenkci, Michael Koldehoff, Anja Gäckler, Peter A. Horn, Fotis Theodoropoulos, Christian Taube, Markus Zettler, Olympia Evdoxia Anastasiou, Peer Braß, Sarah Jansen, Oliver Witzke, Hana Rohn, Adalbert Krawczyk
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2022-10-01
Σειρά:	Frontiers in Immunology
Θέματα:	COVID-19 immunosuppression SARS-CoV-2 monoclonal antibody treatment cellular immune response
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.980698/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!